Photo Credit: Md Saiful Islam Khan
The following is a summary of “Role of Troponin Testing in Patients with Supraventricular Tachycardia, Systematic Review and Meta-Analysis,” published in the November 2024 issue of Emergency Medicine by Pourmand et al.
The Troponin elevation is observed in supraventricular tachycardia (SVT), but its role in predicting coronary artery disease and cardiovascular outcomes remains unclear.
Researchers conducted a retrospective study to examine the prognostic value of troponin measurement in managing SVT in the emergency department (ED).
They searched PubMed and Scopus databases from inception to August 30, 2023, for studies reporting troponin measurements in adult patients (>18 years) presenting to the ED with supraventricular tachycardia (SVT). The primary outcome was the prevalence of elevated troponin in patients with SVT while, the Secondary outcomes were the prevalence of major adverse cardiac events (MACE) and cardiac testing with significant findings.
The results showed the analysis included 7 studies (500 patients), 6 studies were of the number of patients with SVT and elevated troponin, with a pooled prevalence of 46% (95% CI 27–66%, I2 93%). The pooled prevalence of all MACE was 6% (95% CI 1–25%), while the prevalence among patients for MACE with elevated serum troponin levels was 11% (95% CI 4–27%).
Investigators concluded that elevated troponin levels in patients with SVT in ED had low prognostic value for predicting MACE.
Source: sciencedirect.com/science/article/abs/pii/S0736467924001562
